The National Comprehensive Cancer Network (NCCN) recommends testing either the primary tumour or the metastatic lesion based on the results ofseveral studies that highlighted high concordance (> 95%) of KRAS mutations between primary CRCs and their matched metastases [30, 31]. Here, KRAS is linked to neoplasm.